Multienzymatic Hybrid Metalloenzymes Triggering Cascade Reactions-Regulated Tumor Redox Homeostasis and Immunosuppressive Microenvironment for Catalytic Immunotherapy.

Authors

Wanying Sun, Juan Song, Chengyuan Zhu, Xiaolu Guo, Bang-Ping Jiang, Cunji Gao, Xing-Can Shen

Published in

ACS nano. Jun 26, 2025. Epub Jun 26, 2025.

Abstract

Artificial multienzyme systems hold promise for tumor catalytic immunotherapy by a cascade catalyzing the generation of reactive oxygen species (ROS). However, the intricate redox homeostasis restricts ROS accumulation coupled with the immunosuppressive tumor microenvironment (TME), resulting in unsatisfactory therapeutic efficacy. Developing multienzyme systems that can overcome multifaceted TME limitations for effective catalytic immunotherapy is still a significant challenge. Inspired by natural metalloenzymes, herein, a synergistic multienzyme nanoplatform (Co₃S₄@LOx/HA) is constructed by integrating mixed-valent cobalt sulfide (Co₃S₄) nanozymes as artificial cofactors and lactate oxidase (LOx) as protein scaffolds, encapsulated with hyaluronic acid (HA). Through self-cyclic cascade catalysis involving multienzyme activities (LOx, catalase-like, peroxidase-like, and glutathione peroxidase-like activities), Co₃S₄@LOx/HA can concurrently facilitate H₂O₂ and ^•OH generation and deplete intracellular glutathione (GSH). Moreover, Co₃S₄@LOx/HA can also inhibit endogenous thioredoxin reductase (TrxR) activity by the acidic TME-responsive release of hydrogen sulfide (H₂S), further disrupting intracellular redox homeostasis. As a result, the significantly amplified ROS increased double-stranded DNA damage and leakage, thereby activating the stimulator of interferon genes (STING)-related immune responses. Additionally, lactate consumption and O₂ generation during catalytic processes remodeled the immunosuppressive TME. Overall, Co₃S₄@LOx/HA is the first multienzyme nanoplatform that can simultaneously modulate multiple redox homeostasis and the immunosuppressive TME for precise and efficient tumor catalytic immunotherapy. This biomimetic metalloenzyme strategy will inspire more innovative designs of multienzyme nanoplatforms for ROS-mediated tumor therapies.

PMID:
40570303
Bibliographic data and abstract were imported from PubMed on 27 Jun 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.